AstraZeneca expands jobs cuts
Executive Summary
An additional 4,600 positions are being eliminated, AstraZeneca CEO David Brennan says July 26. The company is expanding on an efficiency initiative involving elimination of 3,000 manufacturing jobs begun in March (1"The Pink Sheet" Feb. 5, 2007, p. 15). Cuts to R&D will result from the conclusion of projects in disease areas that AstraZeneca is no longer pursuing and the "creation of a single data management center to drive significant efficiencies by streamlining the way we manage data," Brennan says. Additional reductions come from manufacturing, European sales, and marketing and business support functions...
|
An additional 4,600 positions are being eliminated, AstraZeneca CEO David Brennan says July 26. The company is expanding on an efficiency initiative involving elimination of 3,000 manufacturing jobs begun in March (1 (Also see "AstraZeneca Cuts 3,000 Manufacturing Jobs, Pares Down Therapeutic Areas" - Pink Sheet, 5 Feb, 2007.), p. 15). Cuts to R&D will result from the conclusion of projects in disease areas that AstraZeneca is no longer pursuing and the "creation of a single data management center to drive significant efficiencies by streamlining the way we manage data," Brennan says. Additional reductions come from manufacturing, European sales, and marketing and business support functions.... |